TargetMol中国(陶术生物) 公司信息

公司名称: TargetMol中国(陶术生物)
电话: -
电子邮件:marketing@targetmol.com
国籍:中国
网址: https://www.targetmol.cn/
产品总数:28118

公司提供产品列表

Felzartamab;TJ-202|||MOR-03087|||MOR-202 菲泽妥单抗;TJ-202|||MOR-03087|||MOR-202 2197112-39-1
CCR1/5/8 activator 1; 化合物 CCR1/5/8 activator 1; 4771-50-0
tert-Butyl5-bromo-1H-indole-1-carboxylate;N-Boc-5-bromoindole N-叔丁氧羰基-5-溴吲哚;N-Boc-5-bromoindole 182344-70-3
BRD4-IN-4; 化合物BRD4-IN-4; 304685-40-3
Ulocuplumab;BMS 936564|||MDX 1338 乌洛鲁单抗;BMS 936564|||MDX 1338 1375830-34-4
Garetosmab; 加托索单抗;REGN 2477 2097125-54-5
Bersanlimab;BI-505 Bersanlimab单抗;BI-505 1987854-08-9
Itepekimab;REGN-3500|||SAR-440340 单抗Itepekimab;REGN-3500|||SAR-440340 2226742-52-3
Palivizumab;Synagis|||MEDI 493 帕利珠单抗;Synagis|||MEDI 493 188039-54-5
2-aminobenzo[d]thiazol-6-ol; 2-氨基-6-羟基苯并噻唑; 26278-79-5
Sibrotuzumab;BIBH 1|||Anti-Human FAP Recombinant Antibody 西罗珠单抗;BIBH 1|||Anti-Human FAP Recombinant Antibody 216669-97-5
Mannan; 甘露聚糖; 9036-88-8
Icrucumab;LY 3012212|||IMC-18F1 艾芦库单抗;LY 3012212|||IMC-18F1 1024603-92-6
Flanvotumab;20D7S|||IMC 20D7S 夫兰妥单抗;20D7S|||IMC 20D7S 1188277-05-5
Tafasitamab;MOR00208|||XmAb5574|||Tafasitamab-cxix 塔法西他单抗;MOR00208|||XmAb5574|||Tafasitamab-cxix 1422527-84-1
Tezepelumab;Tezepelumab-ekko|||MEDI 19929|||AMG 157 替西伐单抗;Tezepelumab-ekko|||MEDI 19929|||AMG 157 1572943-04-4
Belantamab;GSK2857914 贝兰妥单抗;GSK2857914 2061894-48-0
Sibeprenlimab; Sibeprenlimab单抗;VIS649|||VIS-649 2382896-07-1
Siplizumab;MEDI-507 西利珠单抗;MEDI-507 288392-69-8
Concizumab;mAb 2021|||NN 7415 康赛珠单抗;mAb 2021|||NN 7415 1312299-39-0
Tesidolumab;LFG316 特度鲁单抗;LFG316 1531594-08-7
Ascrinvacumab;PF-03446962 阿伐苏单抗;PF-03446962 1463459-96-2
Xentuzumab;BI 836845 珍妥珠单抗;BI 836845 1417158-65-6
Narsoplimab;OMS 721 纳索利单抗;OMS 721 2108782-45-0
Spesolimab;BI 655130 司柏索利单抗;BI 655130 2097104-58-8
Nimacimab;JNJ 2463|||RYI-018 尼迈西单抗;JNJ 2463|||RYI-018 2098636-09-8
Nidanilimab; 尼达利单抗;CAN04 2171061-85-9
Praluzatamab; 普罗妥单抗; 2145109-70-0
Clesrovimab;MK-1654 单抗Clesrovimab;MK-1654 2429913-18-6
HDAC-IN-57; 化合物HDAC-IN-57; 2716217-79-5
UK 088800; 化合物UK 088800;5-(2-乙氧苯基)-1-甲基-3-丙基-1,6-二氢-7H-吡唑并[4,3-D]嘧啶-7-酮 139756-21-1
Belimumab;LymphoStat B 贝利尤单抗;LymphoStat B 356547-88-1
Teneliximab;Chi220|||Anti-Human CD40 Recombinant Antibody|||BMS 224819 化合物Teneliximab;Chi220|||Anti-Human CD40 Recombinant Antibody|||BMS 224819 299423-37-3
Ganitumab;AMG 479 加尼妥单抗;AMG 479 905703-97-1
Tisotumab;1E10|||1.00E+10 替索妥单抗;1E10|||1.00E+10 1418628-81-5
Talacotuzumab;CSL 362|||JNJ 56022473 塔妥珠单抗;CSL 362|||JNJ 56022473 1826831-79-1
Ragifilimab;INCAGN-01876|||INCAGN-1876|||CM-701 拉格芙利单抗;INCAGN-01876|||INCAGN-1876|||CM-701 2207590-51-8
TV 3279; 化合物TV 3279; 209394-29-6
Sonepcizumab;LT 1009 Sonepcizumab单抗;LT 1009 1031360-18-5
(Iso)-BMT-124110 Formate;(R)-N-(8-((2-amino-2,4-dimethylpentyl)oxy)-5H-chromeno[3,4-c]pyridin-2-yl)acetamide Formate(1679370-98-9 Free base) 化合物 (Iso)-BMT-124110 Formate;(R)-N-(8-((2-amino-2,4-dimethylpentyl)oxy)-5H-chromeno[3,4-c]pyridin-2-yl)acetamide Formate(1679370-98-9 Free base)
Sodium 2-oxopropanoate;Sodium pyruvate 丙酮酸钠;Sodium pyruvate|||丙酮酸钠 113-24-6
2-Amino-6-bromopyridine; 2-氨基-6-溴吡啶; 19798-81-3
FG-3019; 化合物 FG-3019; 946415-13-0
Carotuximab; 卡妥昔单抗;DE-122|||TRC105 1268714-50-6
Elezanumab;AE12-1Y-QL|||ABT-555 依来努单抗;AE12-1Y-QL|||ABT-555 1791416-49-3
Tomaralimab;OPN-305 托拉利单抗;OPN-305 1449294-76-1
Spartalizumab;PDR001 斯巴达珠单抗;PDR001 1935694-88-4
Enapotamab; Enapotamab单抗; 1912423-61-0
Cobolimab; 考伯利单抗;TSR-022|||GSK4069889 2022215-65-0
Garadacimab;CSL312 加达西单抗;CSL312 2162134-62-3
Latozinemab;GSK-4527223|||AL-001 单抗Latozinemab;GSK-4527223|||AL-001 2376132-27-1
Theralizumab; Theralizumab单抗;TGN1412|||TAB-08|||TABO8 906068-56-2
Clivatuzumab; 克利妥珠单抗; 1622075-09-5
Abciximab;C7E3 阿昔单抗;C7E3 143653-53-6
PLH1215; 化合物 PLH1215; 1332084-64-6
AB21 HCl; AB21盐酸盐;
ACEPROMAZINE MALEATE; 乙酰丙嗪马来酸酯; 3598-37-6
D-Ribose 5-phosphate disodium dihydrate; D-Ribose 5-phosphate 钠盐水合物; 207671-46-3
Suptavumab;REGN2222 舒他伏单抗;REGN2222 1629615-23-1
Ianalumab;VAY-736 伊利尤单抗;VAY-736 1929549-92-7
Quetmolimab;E-6011|||KANAb 001 奎莫利单抗;E-6011|||KANAb 001 2084037-83-0
Telazorlimab;ISB-830|||GBR-830 特拉佐利单抗;ISB-830|||GBR-830 2126777-87-3
Anetumab; 阿奈妥单抗; 1954758-84-9
Ordesekimab;AMG 714|||PRV-015 奥司奇单抗;AMG 714|||PRV-015 879293-15-9
ACHE Inhibitor 12; 化合物 ACHE Inhibitor 12; 66309-83-9
Aducanumab; 阿杜那单抗;BIIB037 1384260-65-4
Butylboronicacid; 正丁基硼酸; 4426-47-5
Andecaliximab;GS-5745 Andecaliximab单抗;GS-5745 1518996-49-0
Plozalizumab; 洛扎利珠单抗;MLN-1202 1610761-46-0
Leronlimab; 乐利单抗;PRO 140 674782-26-4
Nirsevimab; 尼塞韦单抗;MEDI8897 1989556-22-0
Vofatamab;RG-7444|||B-701|||MFGR-1877S 沃凡妥单抗;RG-7444|||B-701|||MFGR-1877S 1312305-12-6
Astegolimab;RG 6149|||MSTT 1041A 艾特利单抗;RG 6149|||MSTT 1041A 2173054-79-8
Nadecnemab;REGN-5069 Nadecnemab单抗;REGN-5069 2377679-19-9
MyD88-IN-1; 化合物MyD88-IN-1; 2911609-80-6
Ramiprilat; 雷米普利; 87269-97-4
Efalizumab;Hu1124|||HU 1124 依法利珠单抗;Hu1124|||HU 1124 214745-43-4
GSNKGAIIGLM(131602-53-4(free base));Amyloid beta-peptide(25-35) BETA-淀粉样蛋白片断25-35;Amyloid beta-peptide(25-35)|||BETA-淀粉样蛋白片断25-35 131602-53-4
Patritumab; 帕曲妥单抗;U3-1287|||AMG-888 1262787-83-6
Oxelumab;Ro 49-89991|||R 4930|||huMAb OX 40L 奥塞芦单抗;Ro 49-89991|||R 4930|||huMAb OX 40L 1186098-83-8
Abrezekimab;UCB4144|||VR 942 阿泽奇单抗;UCB4144|||VR 942 2043952-59-4
Vixarelimab; 单抗Vixarelimab;RG-6536|||RO-7622888|||KPL-716 2243320-83-2
Burfiralimab;hzVSF-v13 化合物 Burfiralimab;hzVSF-v13 2460809-80-5
icFSP1; 化合物IcFSP1; 1115910-36-5
PLH2058; 化合物 PLH2058; 2525206-41-9
Lexatumumab;ETR2-ST01|||DR5 mAB|||HGS-ETR 2 来沙木单抗;ETR2-ST01|||DR5 mAB|||HGS-ETR 2 845816-02-6
Urelumab;BMS-663513|||BMS-66513 乌瑞芦单抗;BMS-663513|||BMS-66513 934823-49-1
Ravulizumab;ALXN1210 雷夫利珠单抗;ALXN1210 1803171-55-2
Otilimab;GSK 3196165|||MOR103 Otilimab单抗;GSK 3196165|||MOR103 1638332-55-4
Vorsetuzumab;SGN-70 沃瑟妥珠单抗;SGN-70 1165740-62-4
Osocimab;BAY 1213790 奥索西单抗;BAY 1213790 2056878-75-0
Cinpanemab;BIIB054 辛帕奈单抗;BIIB054 2094516-02-4
Lecanemab;BAN-2401 仑卡奈单抗;BAN-2401 1260393-98-3
DSPE-NHS; 化合物 DSPE-NHS; 1383932-86-2
5-Nitro-1,10-phenanthroline;5-NP 5-硝基-1,10-菲咯啉;5-NP|||5-硝基-1,10-菲咯啉 4199-88-6
Siltuximab;CNTO-328 司妥昔单抗;CNTO-328 541502-14-1
Erenumab;AMG-334 厄瑞努单抗;AMG-334 1582205-90-0
Donanemab; 化合物 Donanemab; 1931944-80-7
Petosemtamab;MCLA 158 派森妥单抗;MCLA 158 2213450-26-9
Talquetamab;JNJ-64407564|||JNJ-7564 塔奎妥单抗;JNJ-64407564|||JNJ-7564 2226212-40-2
Copyright 2007© ChemicalBook. All rights reserved.